{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T19:25:21Z","timestamp":1790364321799,"version":"4.1.0"},"reference-count":89,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100009947","name":"Merck Sharp and Dohme","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009947","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004334","name":"Merck & Co Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Diagnostic Microbiology and Infectious Disease"],"published-print":{"date-parts":[[2021,11]]},"DOI":"10.1016\/j.diagmicrobio.2021.115473","type":"journal-article","created":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T11:53:12Z","timestamp":1625140392000},"page":"115473","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"title":["In vitro activity of posaconazole and comparators versus opportunistic filamentous fungal pathogens globally collected during 8 years"],"prefix":"10.1016","volume":"101","author":[{"given":"Michael A.","family":"Pfaller","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cecilia G.","family":"Carvalhaes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shawn A.","family":"Messer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul R.","family":"Rhomberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariana","family":"Castanheira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.diagmicrobio.2021.115473_bib0001","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1111\/myc.12222","volume":"57","author":"Abidi","year":"2014","journal-title":"Mycoses"},{"key":"10.1016\/j.diagmicrobio.2021.115473_bib0002","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1007\/s10096-015-2374-1","article-title":"Unpredictable susceptibility of emerging clinical moulds to tri-azoles: review of the literature and upcoming challenges for mould identification","volume":"34","author":"Araujo","year":"2015","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"10.1016\/j.diagmicrobio.2021.115473_bib0003","doi-asserted-by":"crossref","first-page":"e01564","DOI":"10.1128\/JCM.01564-17","article-title":"Update from a 12-Year nationwide fungemia surveillance: increasing intrinsic and acquired resistance causes concern","volume":"56","author":"Astvad","year":"2018","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.diagmicrobio.2021.115473_bib0004","doi-asserted-by":"crossref","first-page":"e02240","DOI":"10.1128\/AAC.02240-17","article-title":"Detection of TR34\/L98H CYP51A mutation through passive surveillance for azole-resistant Aspergillus fumigatus in the United States from 2015 to 2017","volume":"62","author":"Berkow","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.diagmicrobio.2021.115473_bib0005","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.3201\/eid2007.140087","article-title":"Population-based analysis of invasive fungal infections, France, 2001-2010","volume":"20","author":"Bitar","year":"2014","journal-title":"Emerg Infect Dis"},{"key":"10.1016\/j.diagmicrobio.2021.115473_bib0006","doi-asserted-by":"crossref","first-page":"e57","DOI":"10.3390\/jof3040057","article-title":"Global and multi-national prevalence of fungal diseases-estimate precision","volume":"3","author":"Bongomin","year":"2017","journal-title":"J Fungi (Basel)"},{"key":"10.1016\/j.diagmicrobio.2021.115473_bib0007","doi-asserted-by":"crossref","first-page":"103","DOI":"10.3390\/jof4030103","article-title":"Itraconazole, voriconazole, and posaconazole CLSI MIC distributions for wild-type and azole-resistant Aspergillus fumigatus isolates","volume":"4","author":"Buil","year":"2018","journal-title":"J Fungi (Basel)"},{"key":"10.1016\/j.diagmicrobio.2021.115473_bib0008","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1128\/AAC.05414-11","article-title":"Activities of E1210 and comparator agents tested by CLSI and EUCAST broth microdilution methods against Fusarium and Scedosporium species identified using molecular methods","volume":"56","author":"Castanheira","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.diagmicrobio.2021.115473_bib0009","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11046-014-9772-2","article-title":"Isavuconazole and nine comparator antifungal susceptibility profiles for common and uncommon Candida species collected in 2012: application of new CLSI clinical breakpoints and epidemiological cutoff values","volume":"178","author":"Castanheira","year":"2014","journal-title":"Mycopathologia"},{"key":"10.1016\/j.diagmicrobio.2021.115473_bib0010","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.diagmicrobio.2016.02.009","article-title":"Antifungal susceptibility patterns of a global collection of fungal isolates: results of the SENTRY Antifungal Surveillance Program (2013)","volume":"85","author":"Castanheira","year":"2016","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.diagmicrobio.2021.115473_bib0011","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1111\/imj.12600","article-title":"Consensus guidelines for optimising antifungal drug delivery and monitoring to avoid toxicity and improve outcomes in patients with haematological malignancy, 2014","volume":"44","author":"Chau","year":"2014","journal-title":"Intern Med J"},{"key":"10.1016\/j.diagmicrobio.2021.115473_bib0012","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1093\/mmy\/myx066","article-title":"Survey of laboratory practices for diagnosis of fungal infection in seven Asian countries: an Asia Fungal Working Group (AFWG) initiative","volume":"56","author":"Chindamporn","year":"2018","journal-title":"Med Mycol"},{"key":"10.1016\/j.diagmicrobio.2021.115473_bib0013","series-title":"M38Ed3. Reference method for broth dilution antifungal susceptibilty testing of filamentous fungi","year":"2018"},{"key":"10.1016\/j.diagmicrobio.2021.115473_bib0014","series-title":"M59Ed2. Epidemiological cutoff values for antifungal susceptibility testing","year":"2018"},{"key":"10.1016\/j.diagmicrobio.2021.115473_bib0015","series-title":"M61Ed1. Performance standards for antifungal susceptibility testing of filamentous fungi","year":"2018"},{"key":"10.1016\/j.diagmicrobio.2021.115473_bib0016","article-title":"Narrative review of primary care point-of-care testing (POCT) and antibacterial use in respiratory tract infection (RTI)","volume":"2","author":"Cooke","year":"2015","journal-title":"BMJ Open Respir Res"},{"key":"10.1016\/j.diagmicrobio.2021.115473_bib0017","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1056\/NEJMoa061094","article-title":"Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia","volume":"356","author":"Cornely","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.diagmicrobio.2021.115473_bib0018","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1007\/s10096-015-2405-y","article-title":"Emergence of fusarioses in a university hospital in Turkey during a 20-year period","volume":"34","author":"Dalyan Cilo","year":"2015","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"10.1016\/j.diagmicrobio.2021.115473_bib0019","doi-asserted-by":"crossref","first-page":"177","DOI":"10.3201\/eid2302.152042","article-title":"Delivering on antimicrobial resistance agenda not possible without improving fungal diagnostic capabilities","volume":"23","author":"Denning","year":"2017","journal-title":"Emerg Infect Dis"},{"key":"10.1016\/j.diagmicrobio.2021.115473_bib0020","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1002\/j.1875-9114.2012.01124","article-title":"Cost of invasive fungal infections in the era of new diagnostics and expanded treatment options","volume":"32","author":"Dodds Ashley","year":"2012","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.diagmicrobio.2021.115473_bib0021","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1128\/AAC.04435-14","article-title":"Multicenter evaluation of MIC distributions for epidemiologic cutoff value definition to detect amphotericin B, posaconazole, and itraconazole resistance among the most clinically relevant species of Mucorales","volume":"59","author":"Espinel-Ingroff","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.diagmicrobio.2021.115473_bib0022","doi-asserted-by":"crossref","first-page":"3823","DOI":"10.1128\/AAC.00636-13","article-title":"Multicenter study of isavuconazole MIC distributions and epidemiological cutoff values for Aspergillus spp. for the CLSI M38-A2 broth microdilution method","volume":"57","author":"Espinel-Ingroff","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.diagmicrobio.2021.115473_bib0023","doi-asserted-by":"crossref","first-page":"3251","DOI":"10.1128\/JCM.00536-10","article-title":"Wild-type MIC distributions and epidemiological cutoff values for the triazoles and six Aspergillus spp. for the CLSI broth microdilution method (M38-A2 document)","volume":"48","author":"Espinel-Ingroff","year":"2010","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.diagmicrobio.2021.115473_bib0024","doi-asserted-by":"crossref","first-page":"e01916","DOI":"10.1128\/AAC.01916-17","article-title":"Posaconazole MIC distributions for Aspergillus fumigatus species complex by four methods: impact of cyp51A mutations on estimation of epidemiological cutoff values","volume":"62","author":"Espinel-Ingroff","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.diagmicrobio.2021.115473_bib0025","series-title":"Breakpoint tables for interpretation of MICs for antifungal agents, Version 10.0","year":"2020"},{"key":"10.1016\/j.diagmicrobio.2021.115473_bib0026","doi-asserted-by":"crossref","first-page":"67","DOI":"10.3390\/jof5030067","article-title":"Emerging fungal infections: new patients, new patterns, and new pathogens","volume":"5","author":"Friedman","year":"2019","journal-title":"J Fungi (Basel)"},{"key":"10.1016\/j.diagmicrobio.2021.115473_bib0027","doi-asserted-by":"crossref","first-page":"e16","DOI":"10.1093\/cid\/cir485","article-title":"Invasive aspergillosis complicating pandemic influenza A (H1N1) infection in severely immunocompromised patients","volume":"53","author":"Garcia-Vidal","year":"2011","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.diagmicrobio.2021.115473_bib0028","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1111\/myc.12912","article-title":"Systemic antifungal drug use in Belgium-one of the biggest antifungal consumers in Europe","volume":"62","author":"Goemaere","year":"2019","journal-title":"Mycoses"},{"key":"10.1016\/j.diagmicrobio.2021.115473_bib0029","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1007\/s12010-015-1811-z","article-title":"Comparative secretome analysis of Aspergillus niger, Trichoderma reesei, and Penicillium oxalicum during solid-state fermentation","volume":"177","author":"Gong","year":"2015","journal-title":"Appl Biochem Biotechnol"},{"issue":"Suppl 6","key":"10.1016\/j.diagmicrobio.2021.115473_bib0030","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/1469-0691.12539","article-title":"Global trends in the distribution of Candida species causing candidemia","volume":"20","author":"Guinea","year":"2014","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.diagmicrobio.2021.115473_bib0031","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1136\/jcp.2005.034108","article-title":"Audit of laboratory mycology services for the management of patients with fungal infections in the northwest of England","volume":"59","author":"Hassan","year":"2006","journal-title":"J Clin Pathol"},{"key":"10.1016\/j.diagmicrobio.2021.115473_bib0032","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.3201\/eid1507.090043","article-title":"Frequency and evolution of azole resistance in Aspergillus fumigatus associated with treatment failure","volume":"15","author":"Howard","year":"2009","journal-title":"Emerg Infect Dis"},{"key":"10.1016\/j.diagmicrobio.2021.115473_bib0033","series-title":"Manual of Clinical Microbiology","first-page":"1984","article-title":"Candida, Cryptococcus, and other yeasts of medical importants","author":"Howell","year":"2015"},{"key":"10.1016\/j.diagmicrobio.2021.115473_bib0034","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1086\/426445","article-title":"Infections due to Scedosporium apiospermum and Scedosporium prolificans in transplant recipients: clinical characteristics and impact of antifungal agent therapy on outcome","volume":"40","author":"Husain","year":"2005","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.diagmicrobio.2021.115473_bib0035","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1128\/AAC.04223-14","article-title":"Pharmacokinetics and safety study of posaconazole intravenous solution administered peripherally to healthy subjects","volume":"59","author":"Kersemaekers","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.diagmicrobio.2021.115473_bib0036","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1007\/s11046-014-9792-y","article-title":"Posaconazole salvage treatment for invasive fungal infection","volume":"178","author":"Kim","year":"2014","journal-title":"Mycopathologia"},{"key":"10.1016\/j.diagmicrobio.2021.115473_bib0037","doi-asserted-by":"crossref","first-page":"2635","DOI":"10.1128\/AAC.05910-11","article-title":"Species-specific antifungal susceptibility patterns of scedosporium and pseudallescheria species","volume":"56","author":"Lackner","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.diagmicrobio.2021.115473_bib0038","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1128\/JCM.00318-16","article-title":"Role of antifungal susceptibility testing in non-Aspergillus invasive mold infections","volume":"54","author":"Lamoth","year":"2016","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.diagmicrobio.2021.115473_bib0039","doi-asserted-by":"crossref","first-page":"e01244","DOI":"10.1128\/AAC.01244-19","article-title":"Therapeutic challenges of non-Aspergillus invasive mold infections in immunosuppressed patients","volume":"63","author":"Lamoth","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.diagmicrobio.2021.115473_bib0040","doi-asserted-by":"crossref","first-page":"i4","DOI":"10.1093\/jac\/dkx444","article-title":"Changes in the epidemiological landscape of invasive candidiasis","volume":"73","author":"Lamoth","year":"2018","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.diagmicrobio.2021.115473_bib0041","doi-asserted-by":"crossref","first-page":"345","DOI":"10.3390\/jof1030345","article-title":"Role of new antifungal agents in the treatment of invasive fungal infections in transplant recipients: isavuconazole and new posaconazole formulations","volume":"1","author":"Li","year":"2015","journal-title":"J Fungi (Basel)"},{"key":"10.1016\/j.diagmicrobio.2021.115473_bib0042","doi-asserted-by":"crossref","first-page":"379","DOI":"10.2165\/11319340-000000000-00000","article-title":"Pharmacokinetic\/pharmacodynamic profile of posaconazole","volume":"49","author":"Li","year":"2010","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.diagmicrobio.2021.115473_bib0043","doi-asserted-by":"crossref","first-page":"4446","DOI":"10.1128\/AAC.00286-10","article-title":"International retrospective analysis of 73 cases of invasive fusariosis treated with voriconazole","volume":"54","author":"Lortholary","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.diagmicrobio.2021.115473_bib0044","doi-asserted-by":"crossref","first-page":"2524","DOI":"10.1128\/AAC.05959-11","article-title":"Epidemiological cutoff values for azoles and Aspergillus fumigatus based on a novel mathematical approach incorporating cyp51A sequence analysis","volume":"56","author":"Meletiadis","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.diagmicrobio.2021.115473_bib0045","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1128\/AAC.46.1.62-68.2002","article-title":"In vitro activities of new and conventional antifungal agents against clinical Scedosporium isolates","volume":"46","author":"Meletiadis","year":"2002","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.diagmicrobio.2021.115473_bib0046","doi-asserted-by":"crossref","first-page":"e666","DOI":"10.1111\/j.1439-0507.2011.02032.x","article-title":"Emerging moulds: epidemiological trends and antifungal resistance","volume":"54","author":"Miceli","year":"2011","journal-title":"Mycoses"},{"key":"10.1016\/j.diagmicrobio.2021.115473_bib0047","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1586\/17512433.2015.1034689","article-title":"Pharmacologic and clinical evaluation of posaconazole","volume":"8","author":"Moore","year":"2015","journal-title":"Expert Rev Clin Pharmacol"},{"key":"10.1016\/j.diagmicrobio.2021.115473_bib0048","doi-asserted-by":"crossref","first-page":"291","DOI":"10.2147\/IDR.S102207","article-title":"Isavuconazole for the treatment of invasive aspergillosis and mucormycosis: current evidence, safety, efficacy, and clinical recommendations","volume":"9","author":"Natesan","year":"2016","journal-title":"Infect Drug Resist"},{"key":"10.1016\/j.diagmicrobio.2021.115473_bib0049","doi-asserted-by":"crossref","first-page":"e00608","DOI":"10.1128\/AAC.00608-17","article-title":"Triazole resistance is still not emerging in Aspergillus fumigatus isolates causing invasive aspergillosis in Brazilian patients","volume":"61","author":"Negri","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.diagmicrobio.2021.115473_bib0050","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1111\/tid.12060","article-title":"Epidemiology, outcomes, and mortality predictors of invasive mold infections among transplant recipients: a 10-year, single-center experience","volume":"15","author":"Neofytos","year":"2013","journal-title":"Transpl Infect Dis"},{"key":"10.1016\/j.diagmicrobio.2021.115473_bib0052","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1128\/CMR.00014-07","article-title":"Fusarium infections in immunocompromised patients","volume":"20","author":"Nucci","year":"2007","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.diagmicrobio.2021.115473_bib0053","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1111\/1469-0691.12409","article-title":"Improvement in the outcome of invasive fusariosis in the last decade","volume":"20","author":"Nucci","year":"2014","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.diagmicrobio.2021.115473_bib0054","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1179\/joc.2009.21.3.322","article-title":"Zygomycosis in Italy: a survey of FIMUA-ECMM (Federazione Italiana di Micopatologia Umana ed Animale and European Confederation of Medical Mycology)","volume":"21","author":"Pagano","year":"2009","journal-title":"J Chemother"},{"key":"10.1016\/j.diagmicrobio.2021.115473_bib0055","doi-asserted-by":"crossref","first-page":"415","DOI":"10.2146\/ajhp100423","article-title":"Antifungal use in hospitalized adults in U.S. academic health centers","volume":"68","author":"Pakyz","year":"2011","journal-title":"Am J Health Syst Pharm"},{"key":"10.1016\/j.diagmicrobio.2021.115473_bib0056","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.3201\/eid1710.110087","article-title":"Invasive non-Aspergillus mold infections in transplant recipients, United States, 2001-2006","volume":"17","author":"Park","year":"2011","journal-title":"Emerg Infect Dis"},{"issue":"Suppl 6","key":"10.1016\/j.diagmicrobio.2021.115473_bib0057","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1111\/1469-0691.12563","article-title":"Epidemiology of mucormycosis in Europe","volume":"20","author":"Petrikkos","year":"2014","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.diagmicrobio.2021.115473_bib0058","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1177\/1060028015581679","article-title":"Isavuconazole: a new option for the management of invasive fungal infections","volume":"49","author":"Pettit","year":"2015","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.diagmicrobio.2021.115473_bib0059","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1128\/JCM.02136-10","article-title":"Use of epidemiological cutoff values to examine 9-year trends in susceptibility of Aspergillus species to the triazoles","volume":"49","author":"Pfaller","year":"2011","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.diagmicrobio.2021.115473_bib0060","doi-asserted-by":"crossref","first-page":"3551","DOI":"10.1128\/JCM.40.10.3551-3557.2002","article-title":"Role of sentinel surveillance of candidemia: trends in species distribution and antifungal susceptibility","volume":"40","author":"Pfaller","year":"2002","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.diagmicrobio.2021.115473_bib0061","doi-asserted-by":"crossref","first-page":"4419","DOI":"10.1128\/JCM.42.10.4419-4431.2004","article-title":"Rare and emerging opportunistic fungal pathogens: concern for resistance beyond Candida albicans and Aspergillus fumigatus","volume":"42","author":"Pfaller","year":"2004","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.diagmicrobio.2021.115473_bib0062","doi-asserted-by":"crossref","first-page":"S79","DOI":"10.1093\/ofid\/ofy358","article-title":"Twenty years of the SENTRY Antifungal Surveillance Program: results for candida species from 1997-2016","volume":"6","author":"Pfaller","year":"2019","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.diagmicrobio.2021.115473_bib0063","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1128\/AAC.46.4.1032-1037.2002","volume":"46","author":"Pfaller","year":"2002","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.diagmicrobio.2021.115473_bib0064","doi-asserted-by":"crossref","first-page":"2571","DOI":"10.1128\/JCM.00308-13","volume":"51","author":"Pfaller","year":"2013","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.diagmicrobio.2021.115473_bib0065","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.diagmicrobio.2015.04.008","volume":"82","author":"Pfaller","year":"2015","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.diagmicrobio.2021.115473_bib0066","doi-asserted-by":"crossref","first-page":"e01230","DOI":"10.1128\/AAC.01230-18","article-title":"In vitro activity of isavuconazole versus opportunistic fungal pathogens from two mycology reference laboratories","volume":"62","author":"Pfaller","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.diagmicrobio.2021.115473_bib0067","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1007\/s11046-012-9551-x","article-title":"Significance of molecular identification and antifungal susceptibility of clinically significant yeasts and moulds in a global antifungal surveillance programme","volume":"174","author":"Pfaller","year":"2012","journal-title":"Mycopathologia"},{"key":"10.1016\/j.diagmicrobio.2021.115473_bib0068","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.3201\/eid2009.140142","article-title":"Passive surveillance for azole-resistant Aspergillus fumigatus, United States, 2011-2013","volume":"20","author":"Pham","year":"2014","journal-title":"Emerg Infect Dis"},{"key":"10.1016\/j.diagmicrobio.2021.115473_bib0069","doi-asserted-by":"crossref","first-page":"E21","DOI":"10.3390\/jof2030021","article-title":"Triazole resistance in Aspergillus spp.: a worldwide problem?","volume":"2","author":"Rivero-Menendez","year":"2016","journal-title":"J Fungi (Basel)"},{"key":"10.1016\/j.diagmicrobio.2021.115473_bib0070","doi-asserted-by":"crossref","first-page":"2468","DOI":"10.1128\/AAC.00156-08","article-title":"Epidemiological cutoffs and cross-resistance to azole drugs in Aspergillus fumigatus","volume":"52","author":"Rodriguez-Tudela","year":"2008","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.diagmicrobio.2021.115473_bib0071","doi-asserted-by":"crossref","first-page":"e01353","DOI":"10.1128\/JCM.01353-17","article-title":"Multicenter evaluation of the Vitek MS v3.0 system for the identification of filamentous fungi","volume":"56","author":"Rychert","year":"2018","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.diagmicrobio.2021.115473_bib0072","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.3201\/eid1609.100276","article-title":"Increasing incidence of mucormycosis in University Hospital, Belgium","volume":"16","author":"Saegeman","year":"2010","journal-title":"Emerg Infect Dis"},{"key":"10.1016\/j.diagmicrobio.2021.115473_bib0073","doi-asserted-by":"crossref","first-page":"3315","DOI":"10.1093\/jac\/dkz344","article-title":"Matched-paired analysis of patients treated for invasive mucormycosis: standard treatment versus posaconazole new formulations (MoveOn)","volume":"74","author":"Salmanton-Garcia","year":"2019","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.diagmicrobio.2021.115473_bib0074","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.jinf.2019.06.009","article-title":"National mycology laboratory diagnostic capacity for invasive fungal diseases in 2017: evidence of sub-optimal practice","volume":"79","author":"Schelenz","year":"2019","journal-title":"J Infect"},{"key":"10.1016\/j.diagmicrobio.2021.115473_bib0075","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1111\/myc.12631","article-title":"FungiScopeTM - global emerging fungal infection registry","volume":"60","author":"Seidel","year":"2017","journal-title":"Mycoses"},{"key":"10.1016\/j.diagmicrobio.2021.115473_bib0076","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/1040841X.2018.1514366","article-title":"Prognostic factors in 264 adults with invasive Scedosporium spp. and Lomentospora prolificans infection reported in the literature and FungiScope\u00ae","volume":"45","author":"Seidel","year":"2019","journal-title":"Crit Rev Microbiol"},{"key":"10.1016\/j.diagmicrobio.2021.115473_bib0077","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1111\/j.1469-0691.2010.03456.x","article-title":"Zygomycosis in Europe: analysis of 230 cases accrued by the registry of the European Confederation of Medical Mycology (ECMM) working group on zygomycosis between 2005 and 2007","volume":"17","author":"Skiada","year":"2011","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.diagmicrobio.2021.115473_bib0078","doi-asserted-by":"crossref","first-page":"e31801","DOI":"10.1371\/journal.pone.0031801","article-title":"Triazole fungicides can induce cross-resistance to medical triazoles in Aspergillus fumigatus","volume":"7","author":"Snelders","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.diagmicrobio.2021.115473_bib0079","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1186\/s12879-018-3410-4","article-title":"Variability in antifungal utilization among neonatal, pediatric, and adult inpatients in academic medical centers throughout the United States of America","volume":"18","author":"Stultz","year":"2018","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.diagmicrobio.2021.115473_bib0080","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1007\/s10096-014-2111-1","article-title":"European Confederation of Medical Mycology (ECMM) epidemiological survey on invasive infections due to Fusarium species in Europe","volume":"33","author":"Tortorano","year":"2014","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"10.1016\/j.diagmicrobio.2021.115473_bib0081","doi-asserted-by":"crossref","first-page":"2867","DOI":"10.1093\/jac\/dky270","article-title":"Trends in antifungal use in US hospitals, 2006-12","volume":"73","author":"Vallabhaneni","year":"2018","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.diagmicrobio.2021.115473_bib0082","doi-asserted-by":"crossref","first-page":"ofw268","DOI":"10.1093\/ofid\/ofw268","article-title":"Trends in hospitalizations related to invasive aspergillosis and mucormycosis in the United States, 2000-2013","volume":"4","author":"Vallabhaneni","year":"2017","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.diagmicrobio.2021.115473_bib0083","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.3201\/eid2106.140717","article-title":"Prospective multicenter international surveillance of azole resistance in Aspergillus fumigatus","volume":"21","author":"van der Linden","year":"2015","journal-title":"Emerg Infect Dis"},{"key":"10.1016\/j.diagmicrobio.2021.115473_bib0084","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1093\/cid\/civ885","article-title":"Azole resistance in Aspergillus fumigatus: can we retain the clinical use of mold-active antifungal azoles?","volume":"62","author":"Verweij","year":"2016","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.diagmicrobio.2021.115473_bib0085","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1086\/508774","article-title":"Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: an externally controlled trial","volume":"44","author":"Walsh","year":"2007","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.diagmicrobio.2021.115473_bib0086","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1007\/s00134-012-2673-2","article-title":"Invasive pulmonary aspergillosis is a frequent complication of critically ill H1N1 patients: a retrospective study","volume":"38","author":"Wauters","year":"2012","journal-title":"Intensive care medicine"},{"key":"10.1016\/j.diagmicrobio.2021.115473_bib0087","series-title":"Manual of Clinical Microbiology","first-page":"2057","article-title":"Fusarium and other opportunitistic hyaline fungi","author":"Zhang","year":"2015"},{"key":"10.1016\/j.diagmicrobio.2021.115473_bib0088","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1093\/cid\/ciy181","article-title":"Epidemiology and outcomes of hospitalizations with invasive Aspergillosis in the United States, 2009-2013","volume":"67","author":"Zilberberg","year":"2018","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.diagmicrobio.2021.115473_bib0089","doi-asserted-by":"crossref","first-page":"516","DOI":"10.3389\/fmicb.2018.00516","article-title":"Azole-resistance in Aspergillus terreus and related species: an emerging problem or a rare phenomenon?","volume":"9","author":"Zoran","year":"2018","journal-title":"Front Microbiol"},{"key":"10.1016\/j.diagmicrobio.2021.115473_bib0051","unstructured":"Noxafil (Posaconazole-product monograph). 2014. Available at: https:\/\/www.merck.com\/product\/usa\/pi_circulars\/n\/noxafil\/noxafil_pi.pdf. Accessed June 26, 2021."}],"container-title":["Diagnostic Microbiology and Infectious Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0732889321001668?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0732889321001668?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T09:56:47Z","timestamp":1760003807000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0732889321001668"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11]]},"references-count":89,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,11]]}},"alternative-id":["S0732889321001668"],"URL":"https:\/\/doi.org\/10.1016\/j.diagmicrobio.2021.115473","relation":{},"ISSN":["0732-8893"],"issn-type":[{"value":"0732-8893","type":"print"}],"subject":[],"published":{"date-parts":[[2021,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"In vitro activity of posaconazole and comparators versus opportunistic filamentous fungal pathogens globally collected during 8 years","name":"articletitle","label":"Article Title"},{"value":"Diagnostic Microbiology and Infectious Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.diagmicrobio.2021.115473","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"115473"}}